ZIA CP010214-10068 (ZIA) | |||
---|---|---|---|
Title | Hemophilia studies | ||
Institution | NCI, Bethesda, Ma | ||
Principal Investigator | Goedert, Jim | NCI Program Director | N/A |
Cancer Activity | N/A | Division | DCEG |
Funded Amount | $92,525 | Project Dates | 01/24/2004 - N/A |
Fiscal Year | 2011 | Project Type | Intramural |
Research Topics w/ Percent Relevance | Cancer Types w/ Percent Relevance | ||
Autoimmune Diseases (10.0%) Biochemical Epidemiology (45.0%) Cancer (100.0%) |
N/A | ||
Research Type | |||
Exogenous Factors in the Origin and Cause of Cancer Endogenous Factors in the Origin and Cause of Cancer |
|||
Abstract | |||
The first Multicenter Hemophilia Cohort Study (MHCS-I, 1982û2000) provided substantial insights on the epidemiology and natural history of HIV. The Second MHCS (MHCS-II, 2001û2005) focused primarily on defining the natural history of hepatitis C virus (HCV) infection, and secondarily on later complications of HIV and combination antiretroviral therapy (cART). Field work was terminated in 2005, primarily because few major HCV- or HIV-related events were being observed. To expand use of the substantial data and specimens that I had collected, and to save money, in 2010 the entire MHCS-I/-II repository and copies of all corresponding data sets were transferred to the extramural Division of Blood Diseases and Resources of NHLBI. Collaborative analyses have continued in recent years, generally at a low level, on human genetics and other projects that use the data, DNA, and other specimens from MHCS-I/-II. These include intensive HIV/AIDS investigations of HLA and related genes, especially the killer immunoglobulin-like receptor (KIR) genes; verification of associations of NCOR2 and IDH1 with HIV acquisition; a GWAS of HIV/AIDS and its complications, the first results of which have been published; candidate-gene and GWAS studies of HCV and hepatitis B virus, including the high-impact discovery that the CC allele of the IL28B gene (which codes for interferon-λ3) markedly increased spontaneous HCV clearance; candidate genes for development of neutralizing anti-factor VIII antibodies (inhibitors); and investigations of resistance to HIV infection, with particular focus on MHCS-I/-II participants who escaped HIV infection despite intensive exposure to contaminated clotting factor concentrates. The latter includes whole genome and whole exome sequencing of very high-risk, HIV-negative subjects. |